Scientists crack the code to tamoxifen resistance
Heart failure is reaching epidemic levels among seniors in the United States, according to research presented at the American Heart Association’s Scientific Sessions 2008. “Both the number of patients hospitalized with a primary diagnosis of heart failure and age-adjusted hospitalization rates for heart failure have increased dramatically over the past 27 years,” said Longjian Liu,
Full Post: Heart failure hospitalization rates rise among nation’s seniors
CANCER RESEARCH UK scientists have discovered the molecular basis for tamoxifen response in breast cancer cells - and the reason why some women can develop resistance to the treatment, according to a study published in Nature today (Wednesday).
Tamoxifen is given to most women for five years after they are first diagnosed with breast cancer to help prevent the disease from coming back but some women develop resistance to the treatment after time, meaning their cancer is more likely to return.
Researchers at the Cancer Research UK Cambridge Research Institute have discovered for the first time the mechanism by which the breast cancer therapy tamoxifen operates. It switches off a breast cancer gene ErbB2 via a protein called Pax2. Pax2 acts as a ’switch’ to keep ErbB2 switched off. Tamoxifen resistance occurs when ErbB2 remains switched on.
Previously it was known that tamoxifen worked by blocking oestrogen from causing unchecked cell growth in breast cancer by switching certain genes on but the mechanism by which this occurred was unknown.
Lead author, Dr Jason Carroll said: “We knew that women developed resistance to tamoxifen but previously our understanding of why this occurred could be compared with trying to fix a broken car without knowing how the engine worked. Now we understand how all the engine parts operate and we can try to think about ways to make repairs.
“We have discovered that for tamoxifen to work it has to block the gene ErbB2 and it does this by using a control switch that is hidden in the background of the genome, within the ErbB2 gene itself. In order for tamoxifen to be effective, this switch must be held in the off position by Pax2. Now we understand how women can develop tamoxifen resistance.”
The production of oestrogen can cause breast cancer cells to grow and divide but tamoxifen prevents oestrogen from causing breast cancer cells to grow, helping to lower the risk of the disease returning. Most women have breast cancers that are stimulated to grow by oestrogen but not all.
Breast cancer is the most common cancer in women in the UK. More than 45,500 women are diagnosed with the disease each year - 125 women a day, and the disease causes almost 12,500 deaths each year. Eight in 10 cases of breast cancer are diagnosed in women over the age of 50.
Professor Sir David Lane, Cancer Research UK’s chief scientist said: “Cancer Research UK’s early clinical trials of tamoxifen helped transform the way that women were treated for early breast cancer saving ten’s of thousands of lives, and this work is yet another step forward.
“More women are surviving breast cancer than ever before thanks to improvements in diagnosis and treatment as well as important fundamental science discoveries like this.”
He added: “Tamoxifen has been a huge success story helping to prevent breast cancer recurring for many women.
“Understanding why it occasionally stops working is really important because it allows us to identify new targets for drug development and who will need such treatments.”
The power of the drug tamoxifen to reduce breast density is key in preventing breast cancer - according to a presentation in America by Cancer Research UK scientists. Researchers monitored the extent to which tamoxifen could reduce breast density in 7000 healthy post menopausal women who are at high risk of breast cancer in a
Full Post: How tamoxifen prevents breast cancer in some women but not others
Tamoxifen may worsen breast cancer in a small subset of patients. Research published in BioMed Central’s open access journal Breast Cancer Research suggests that in patients who show reduced or absent expression of the protein E-cadherin, commonly used anti-oestrogen drugs such as tamoxifen may promote more harmful cancer cell behaviour. A team of researchers co-ordinated
Full Post: Anti-oestrogen drugs may promote more harmful cancer cell behaviour
Women who have a strong family history of breast cancer are over four times more likely to develop the disease than the general population, according to research published in the British Journal of Cancer. This is the first time the risk for women who do not have a faulty BRCA gene but have one first-degree
Full Post: Breast cancer four times more likely in women with strong family history
Mayo Clinic researchers have discovered that a chemical known as endoxifen appears to be the primary metabolite responsible for the effectiveness of tamoxifen in treating breast cancer, and that it works against cancer in an entirely unexpected way. Their study, being presented at the Cancer Therapy & Research Center-American Association for Cancer Research (CTRC-AACR) 31st
Full Post: Researchers find tamoxifen’s power comes from endoxifen
CANCER RESEARCH UK scientists have shown for the first time how a natural ‘defence’ gene involved in fighting infections such as common colds, can be triggered by hormones to ignite and drive cancers like breast, ovarian, and possibly prostate cancer. Their findings are published in the Journal of Experimental Medicine. A team of researchers at
Full Post: Natural ‘defence’ gene reveals how oestrogen fuels cancer